Last reviewed · How we verify
High Metformin
At a glance
| Generic name | High Metformin |
|---|---|
| Also known as | Metformin, Leucine, L-Leucine, Metformin, Leucine, L-Leucine |
| Sponsor | NuSirt Biopharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function (PHASE2)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults (PHASE1)
- Safety and Feasibility of Metformin for Sepsis Induced AKI (PHASE2)
- A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury (PHASE1)
- Blood Markers of Early Pancreas Cancer
- Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes (PHASE2)
- A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High Metformin CI brief — competitive landscape report
- High Metformin updates RSS · CI watch RSS
- NuSirt Biopharma portfolio CI